Independent Solutions Wealth Management LLC Has $429,000 Stake in Becton, Dickinson and Company (NYSE:BDX)

Independent Solutions Wealth Management LLC lessened its position in Becton, Dickinson and Company (NYSE:BDX) by 8.7% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,780 shares of the medical instruments supplier’s stock after selling 170 shares during the period. Independent Solutions Wealth Management LLC’s holdings in Becton, Dickinson and Company were worth $429,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of the company. Livelsberger Financial Advisory acquired a new stake in shares of Becton, Dickinson and Company in the third quarter valued at approximately $26,000. Ashton Thomas Securities LLC acquired a new stake in shares of Becton, Dickinson and Company in the third quarter valued at approximately $33,000. Tompkins Financial Corp increased its position in Becton, Dickinson and Company by 44.2% during the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock worth $36,000 after acquiring an additional 46 shares during the period. Sound Income Strategies LLC grew its position in shares of Becton, Dickinson and Company by 35.8% during the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 44 shares in the last quarter. Finally, Kennebec Savings Bank acquired a new stake in Becton, Dickinson and Company during the third quarter worth approximately $46,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Up 0.2 %

Shares of Becton, Dickinson and Company stock traded up $0.46 during midday trading on Thursday, hitting $224.55. The company had a trading volume of 1,631,786 shares, compared to its average volume of 1,478,469. The stock has a market capitalization of $64.92 billion, a P/E ratio of 37.80, a P/E/G ratio of 1.64 and a beta of 0.41. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.74 and a current ratio of 1.17. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $249.89. The company has a 50 day moving average of $230.29 and a 200 day moving average of $233.34.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, beating the consensus estimate of $3.77 by $0.04. The firm had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The company’s revenue was up 6.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.42 EPS. On average, equities analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 31st. Stockholders of record on Monday, December 9th will be given a dividend of $1.04 per share. The ex-dividend date is Monday, December 9th. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.85%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 70.03%.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on BDX. StockNews.com downgraded Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Wednesday. Evercore ISI raised their price target on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Finally, Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $255.00 to $275.00 in a research note on Tuesday, October 1st. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of “Moderate Buy” and a consensus target price of $283.50.

Insider Activity at Becton, Dickinson and Company

In other news, EVP Roland Goette sold 638 shares of the business’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $219.03, for a total value of $139,741.14. Following the completion of the transaction, the executive vice president now owns 14,217 shares of the company’s stock, valued at $3,113,949.51. The trade was a 4.29 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.31% of the stock is owned by corporate insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.